EspeRare gains rights to relaunch late stage development for XLHED
Caroline Kant - participating Ashoka fellow to 2016 Health and Lighting Globalizer Program - annouced this week a pivotal partnership between EspeRare and Edimer Pharmaceuticals Inc. Caroline as founder and CEO of EspeRare conveyed this successful partnership as an essential opportunity to continue the development of ER-004, an innovative therapy for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder. Thanks to the impressive results obtained by Professor Holm Schneider when treating prenatally three affected babies, EspeRare will be able to lauch an a late-stage clinical develoment aimed at securigin early marketing approval.
“This is such an exciting time for the EspeRare team which warmly thanks all of its supporters who contributed greatly to giving a second life to this therapy, bringing back hope to the XLHED patient community” said Caroline Kant, Founder and CEO of EspeRare. She added that “This innovative treatment approach has the potential to fundamentally change the lives of these patients and may also pave the way for other prenatal treatments to correct genetic diseases before birth.”
By founding EspeRare in 2013, Caroline incentivizes investments in drug repositioning by pooling additional financial resources from public funds, patient groups, as well as by reducing R&D costs, therefore de-risking the validation of these unexplored opportunities in rare diseases.